ReliaWireG2 Quiescent Brain Stem Cells Have High Regenerative PotentialReliaWireA new type of stem cell in the brain has been identified by scientists at the Wellcome Trust/ Cancer Research UK Gurdon Institute, which they say has a high potential for r… Continue reading
Tech TimesGene Therapy Could Be Key To Survival Of Astronauts In Deep Space Mission To MarsTech TimesArtificial intelligence can help identify which cells in the body are more resistant to radiation, and it would allow researchers to fortify them using… Continue reading
Tech TimesGene Therapy Could Be Key To Survival Of Astronauts In Deep Space Mission To MarsTech TimesArtificial intelligence can help identify which cells in the body are more resistant to radiation, and it would allow researchers to fortify them using… Continue reading
ReliaWireNovel method to generate stem cells developed | Business Standard …Business StandardRead more about Novel method to generate stem cells developed on Business Standard. Chinese scientists have developed a novel method by mixing two chemicals … Continue reading
BioSci Rounds Report: Elucidating Crispr Fundamentals Improvement And Opko Health ProspectsSeeking AlphaNotably, the FDA approval re Luxturna of Sparks Therapeutics (NASDAQ:ONCE) foretells the coming of more gene therapy as well as gene editing molecul… Continue reading
XinhuaChinese scientists find new method to induce stem cellsXinhuaBEIJING, April 8 (Xinhua) — Chinese scientists have made a breakthrough in creating stem cells with a cocktail of two chemicals that can induce mature somatic cells to turn back into p… Continue reading
Seeking Alpha |
Adverem Biotechnologies: Gene Therapy Company And Our New Buy
Seeking Alpha We bought shares of Adverem Biotechnologies (ADVM). The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price … Adverum Biotechnologies Inc. (ADVM) Plunges 6.03% on April 06Equities.com Analysts’ Weekly Ratings Changes for Adverum Biotechnologies (ADVM)Week Herald Adverum Biotechnologies (NASDAQ:ADVM) Downgraded to Hold at Zacks Investment ResearchStockNewsTimes |
Seeking Alpha |
Adverum Biotechnologies: Gene Therapy Company And Our New …
Seeking Alpha The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price target = $18. We bought shares of Adverum … Adverum Biotechnologies, Inc. (ADVM) Declined to $5.45 on Apr, 8Houston Style On Fleek What’s Adverum Biotechnologies, Inc. (ADVM) Downside After Today’s Significant Decline?NMSU Herald Zacks Premium Investment Service – Zacks.comZacks |